Equities

Cue Biopharma Inc

Cue Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.49
  • Today's Change-0.21 / -12.35%
  • Shares traded529.62k
  • 1 Year change-37.66%
  • Beta1.7467
Data delayed at least 15 minutes, as of Nov 13 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
REVENUE AND GROSS PROFIT
Total revenue5.491.2515
OPERATING EXPENSES
Cost of revenue total------
Selling, general and admin. expenses, total171617
Depreciation/amortization0.550.831.17
Unusual expense(income)0.16(0.28)--
Other operating expenses, total------
Total operating expense585459
Operating income(52)(53)(44)
Other, net------
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes(51)(53)(44)
Provision for income taxes--00.50
Net income after taxes(51)(53)(44)
Minority interest------
Net income before extra. Items(51)(53)(44)
Total extraordinary items------
Net income(51)(53)(44)
Inc.avail. to common excl. extra. Items(51)(53)(44)
Inc.avail. to common incl. extra. Items(51)(53)(44)
EPS RECONCILIATION
Basic/primary weighted average shares463631
Basic/primary eps excl. extra items(1.11)(1.49)(1.41)
Basic/primary eps incl. extra items(1.11)(1.49)(1.41)
Dilution adjustment------
Diluted weighted average shares463631
Diluted eps excl. extra items(1.11)(1.49)(1.41)
Diluted eps incl. extra items(1.11)(1.49)(1.41)
COMMON STOCK DIVIDENDS
DPS - common stock primary issue------
Gross dividend - common stock000
PRO FORMA INCOME
Pro forma net income------
Interest expense, supplemental1.250.71--
SUPPLEMENTAL INCOME
Depreciation, supplemental0.550.830.91
Total special items0.16(0.28)(0.02)
NORMALISED INCOME
Normalized income before taxes(51)(53)(44)
Effect of special items on income taxes00(0.01)
Income tax excluding impact of special items000.49
Normalized income after tax(51)(53)(44)
Normalized income avail. to common(51)(53)(44)
Basic normalized EPS(1.11)(1.49)(1.41)
Diluted normalized EPS(1.11)(1.49)(1.41)
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.